According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:
- The materials submitted in support of the pimavanserin supplemental New Drug Application (“sNDA”) contained statistical and design deficiencies;
- Accordingly, the pimavanserin sNDA lacked the evidentiary support that the Company had led investors to believe it possessed;
- The FDA was unlikely to approve the pimavanserin sNDA in its present form; and
- As a result, the Company’s public statements were materially false and misleading at all relevant times.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.